Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 47

References for PMC Articles for PubMed (Select 21630083)


Microfluidic-based 18F-labeling of biomolecules for immuno-positron emission tomography.

Liu K, Lepin EJ, Wang MW, Guo F, Lin WY, Chen YC, Sirk SJ, Olma S, Phelps ME, Zhao XZ, Tseng HR, Michael van Dam R, Wu AM, Shen CK.

Mol Imaging. 2011 Jun;10(3):168-76, 1-7.


Development trends for human monoclonal antibody therapeutics.

Nelson AL, Dhimolea E, Reichert JM.

Nat Rev Drug Discov. 2010 Oct;9(10):767-74. doi: 10.1038/nrd3229. Epub 2010 Sep 3. Review.


A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth.

Wiiger MT, Gehrken HB, Fodstad Ø, Maelandsmo GM, Andersson Y.

Cancer Immunol Immunother. 2010 Nov;59(11):1665-74. doi: 10.1007/s00262-010-0892-3. Epub 2010 Jul 16.


Preclinical evaluation of monoclonal antibody 14C5 for targeting pancreatic cancer.

Vervoort L, Burvenich I, Staelens S, Dumolyn C, Waegemans E, Van Steenkiste M, Baird SK, Scott AM, De Vos F.

Cancer Biother Radiopharm. 2010 Apr;25(2):193-205. doi: 10.1089/cbr.2009.0696.


68Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours.

Eder M, Knackmuss S, Le Gall F, Reusch U, Rybin V, Little M, Haberkorn U, Mier W, Eisenhut M.

Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1397-407. doi: 10.1007/s00259-010-1392-6. Epub 2010 Feb 16.


A modeling analysis of the effects of molecular size and binding affinity on tumor targeting.

Schmidt MM, Wittrup KD.

Mol Cancer Ther. 2009 Oct;8(10):2861-71. doi: 10.1158/1535-7163.MCT-09-0195.


Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research.

Anderson CJ, Ferdani R.

Cancer Biother Radiopharm. 2009 Aug;24(4):379-93. doi: 10.1089/cbr.2009.0674.


Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse.

Kahlert C, Weber H, Mogler C, Bergmann F, Schirmacher P, Kenngott HG, Matterne U, Mollberg N, Rahbari NN, Hinz U, Koch M, Aigner M, Weitz J.

Br J Cancer. 2009 Aug 4;101(3):457-64. doi: 10.1038/sj.bjc.6605136. Epub 2009 Jul 14.


Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model.

Hausner SH, Abbey CK, Bold RJ, Gagnon MK, Marik J, Marshall JF, Stanecki CE, Sutcliffe JL.

Cancer Res. 2009 Jul 15;69(14):5843-50. doi: 10.1158/0008-5472.CAN-08-4410. Epub 2009 Jun 23.


Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET).

Shokeen M, Anderson CJ.

Acc Chem Res. 2009 Jul 21;42(7):832-41. doi: 10.1021/ar800255q.


Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.

Ahlgren S, Wållberg H, Tran TA, Widström C, Hjertman M, Abrahmsén L, Berndorff D, Dinkelborg LM, Cyr JE, Feldwisch J, Orlova A, Tolmachev V.

J Nucl Med. 2009 May;50(5):781-9. doi: 10.2967/jnumed.108.056929. Epub 2009 Apr 16.


Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma.

Strickland LA, Ross J, Williams S, Ross S, Romero M, Spencer S, Erickson R, Sutcliffe J, Verbeke C, Polakis P, van Bruggen N, Koeppen H.

J Pathol. 2009 Jul;218(3):380-90. doi: 10.1002/path.2545.


Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer.

Kulasingam V, Zheng Y, Soosaipillai A, Leon AE, Gion M, Diamandis EP.

Int J Cancer. 2009 Jul 1;125(1):9-14. doi: 10.1002/ijc.24292.


In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice.

Schneider DW, Heitner T, Alicke B, Light DR, McLean K, Satozawa N, Parry G, Yoo J, Lewis JS, Parry R.

J Nucl Med. 2009 Mar;50(3):435-43. doi: 10.2967/jnumed.108.055608. Epub 2009 Feb 17.


Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients.

Sawhney M, Matta A, Macha MA, Kaur J, DattaGupta S, Shukla NK, Ralhan R.

Int J Cancer. 2009 May 1;124(9):2098-105. doi: 10.1002/ijc.24192.


Antibodies and antimatter: the resurgence of immuno-PET.

Wu AM.

J Nucl Med. 2009 Jan;50(1):2-5. doi: 10.2967/jnumed.108.056887. Epub 2008 Dec 17. Review.


Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2.

Sirk SJ, Olafsen T, Barat B, Bauer KB, Wu AM.

Bioconjug Chem. 2008 Dec;19(12):2527-34. doi: 10.1021/bc800113v.


Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors.

Leyton JV, Olafsen T, Sherman MA, Bauer KB, Aghajanian P, Reiter RE, Wu AM.

Protein Eng Des Sel. 2009 Mar;22(3):209-16. doi: 10.1093/protein/gzn055. Epub 2008 Oct 28.


Preoperative evaluation of pancreatic adenocarcinoma.

Parsons CM, Sutcliffe JL, Bold RJ.

J Hepatobiliary Pancreat Surg. 2008;15(4):429-35. doi: 10.1007/s00534-007-1240-7. Epub 2008 Aug 1. Review.


Antibodies for molecular imaging of cancer.

Wu AM, Olafsen T.

Cancer J. 2008 May-Jun;14(3):191-7. doi: 10.1097/PPO.0b013e31817b07ae. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk